Pfizer's Antiviral COVID-19 Clinical Trials
Explore Pfizer's Antiviral COVID-19 Clinical Trials as potential options for your patients with COVID-19.
Recruiting
ASPIRE-HR (High Risk)
ASPIRE-HR is a Phase 3 clinical trial evaluating oral ibuzatrelvir in non-hospitalized, symptomatic adult (18+) and adolescent (12+) participants with COVID-19 who are at high risk of progressing to severe illness due to underlying risk factors.
These risk factors include:
- BMI ≥30 kg/m2
- Current smoker
- Chronic lung disease
- Asthma requiring daily prescribed therapy
- Cardiovascular disease
- Type 1 or Type 2 diabetes
- Mild to moderate renal impairment
- Neurodevelopmental disorders
- Sickle cell disease
- Moderate immunosuppression
Additional requirements apply.
Recruiting
ASPIRE-IC (Immunocompromised)
ASPIRE-IC is a Phase 3 clinical trial evaluating oral ibuzatrelvir in adults (18+) with symptomatic COVID-19 who are severely immunocompromised.
This clinical trial is enrolling patients who are immunocompromised due to:
- Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy
- Active hematologic malignancy (e.g., chronic lymphocytic lymphoma, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
- Receipt of CAR-T cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy
- Currently receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, epratuzmab)
Additional requirements apply.